P829: A PHASE III RANDOMIZED CLINICAL TRIAL COMPARING SB12 (PROPOSED ECULIZUMAB BIOSIMILAR) WITH REFERENCE ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

• J. H. Jang,
• R. Demichelis Gomez,
• H. Bumbea,
• L. Nogaieva,
• L. L. L. Wong,
• S. M. Lim,
• J. Park,
• Y. Kim,
• S. Cho

Affiliations

J. H. Jang

1 Hematology-Oncology, Samsung Medical Center, Seoul, South Korea

R. Demichelis Gomez

2 Hematology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico

H. Bumbea

3 Hematology, Bucharest Emergency University Hospital, Bucharest, Romania

L. Nogaieva

4 Regional Treatment-Diagnostic Hematology Center, Communal Nonprofit Enterprise Cherkasy Regional Oncology Dispensary of Cherkasy Oblast Council, Cherkasy, Ukraine

L. L. L. Wong

5 Hematology Unit, Hospital Queen Elizabeth, Kota Kinabalu

S. M. Lim

6 Department of Medicine, Hospital Sultanah Aminah, Johor Bahru, Malaysia

J. Park

7 Clinical Development

Y. Kim

8 Biometrics, Samsung Bioepis, Incheon, South Korea

S. Cho

7 Clinical Development